| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8739575 | Journal of Autoimmunity | 2018 | 8 Pages |
Abstract
We demonstrate a protective role for CD39 in APS and provide rationale for both the development of endothelial cell-targeted soluble CD39 as a novel therapeutic for APS and analysis of perturbations in the purinergic pathway to explain human disease.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Anushka N. Samudra, Karen M. Dwyer, Carly Selan, Susanna Freddi, Lisa Murray-Segal, Mandana Nikpour, Michael J. Hickey, Karlheinz Peter, Simon C. Robson, Maithili Sashindranath, Peter J. Cowan, Harshal H. Nandurkar,